Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis

This publication has 15 references indexed in Scilit:

• Changing concepts of medical treatment of endometriosis
  Acta Obstetricia et Gynecologica Scandinavica, 1993
• Treatment of endometriosis
  The Lancet, 1992
• A Comparative Treatment Trial of Endometriosis Using the Gonadotrophin‐releasing Hormone Agonist, Nafarelin, and the Synthetic Steroid, Danazol
  Australian and New Zealand Journal of Obstetrics and Gynaecology, 1991
• Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate
  European Journal of Obstetrics & Gynecology and Reproductive Biology, 1990
• Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists?
  Journal of Clinical Endocrinology & Metabolism, 1990
• Induction of Pharmacological Hypogonadotropism Using Gonadotropin-Releasing Hormone Agonists in Patients Undergoing Controlled Ovarian Stimulation
  Gynecologic and Obstetric Investigation, 1990
• Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis
  New England Journal of Medicine, 1988
• Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis
  Gynecological Endocrinology, 1987
• PHYSIOLOGY OF PROLACTIN
  Clinical Obstetrics and Gynecology, 1980
• Post-Menopausal Osteopenia and Osteoporosis
  Published by S. Karger AG ,1974